Trace-Ability’s Leadership Team

Our leadership team consists of thought leaders and industry experts with proven track records of success.

 

Arkadij Elizarov, PhD
CEO

As CEO of Trace-Ability, Inc., Arkadij Elizarov has been setting the company vision and leading all business development and operational activities. He has acquired the first customers, for whom the company has completed projects generating profits that were invested into product development. Subsequently he has secured angel investments and grant funding which allowed Trace-Ability to move from early proof of concept to mature fully functional prototypes of Tracer-QC installed in customer facilities. Arkadij has established critical industry relationships needed for success of Trace-Ability’s go-to-market strategy.

In 2013 Arkadij exited Siemens after 7 years with multiple leadership awards as Sr. Director, Clinical Operations, accountable for the execution of all clinical trials with PET imaging agents developed at Siemens. He was responsible for GCP compliance of clinical operations, budget forecasting and performance, staffing and organizational structure, data quality and regulatory filings as well as operational efficiency. Earlier, as Director of Biomarker Instrumentation Engineering, Arkadij led a group that has developed a number of radio-synthesis and analytical instruments for radio-pharmaceutical applications. Earlier, as a scientist, Dr. Elizarov has pioneered a radical new radio-pharmaceutical synthesis technology highlighted by first preclinical and clinical validations reported in Science Magazine (2005) and Lab-on-a-Chip (2010). Dr. Elizarov is an inventor on 19 issued patents. Prior to Siemens, Dr. Elizarov has held scientific and project management positions at the California Institute of Technology and Galileo Pharmaceuticals, Inc.

Dr. Elizarov holds a PhD degree in Organic Chemistry from UCLA and a current PMP certification from the Project Management Institute.

Artem Lebedev, PhD
CTO
Artem Lebedev is a visionary capable of generating unprecedented innovation to solve pressing industry issues with elegantly simple solutions.  As CTO of Trace-Ability, Inc., he has established the technology vision, reduced it to practice and taken it through several pivoting points to enable the product concept to deliver the most impact to the customers.  He has been effective both as a hands-on scientist and a leader of a heterogeneous group of specialists.  Artem has also been driving the company’s IP strategy definition and implementation. Artem has been awarded multiple government grants that supported his research.

Dr. Artem Lebedev received his PhD in Organic Chemistry from Moscow State University. In 2006 Dr. Lebedev moved to the University of Pennsylvania to expand his research into the field of molecular imaging. Since then he has worked in the field of molecular imaging of hypoxia and acidosis, with emphasis on Positron Emission Tomography (PET) probe development and instrumentation. His expertise spans all areas of molecular imaging, from probe optimization to clinical production and regulatory affairs.

In the field of radiochemistry instrumentation Dr. Lebedev is known for the development of the protocols for the first microfluidic apparatus used in production of clinical radiotracer, which he achieved as a Staff Scientist at Siemens Molecular Imaging. As a recognized expert in the field he was invited to contribute a chapter to the book on microfluidic applications in life science, published in 2013.

CFO

Trace-Ability’s CFO has led the development of the business case and financial model to optimize the efficiency and align both with the target markets. Besides extensive experience, he brings with him a high level of financial discipline which is rarely feasible in early start-ups.

A seasoned Finance executive with over 20 years’ experience in building and leading finance and administrative organizations in Fortune 500 and start-up companies, he spearheaded a number of private financing rounds, managed acquisitions and divestitures, and negotiated a number of successful partnership transactions. He has been involved with Life Sciences companies, including Amgen for most of his career, and has CFO experience at a successful PET technology company. He holds an MBA degree from Marshall School of Business at USC, and a Bachelor’s Degree in Chemistry.

Advisory Board

 

Thomas Brady, MD

Director, Division of Nuclear Medicine & Molecular Imaging & PET-CT;
Vice Chairman, Radiology Research:
Massachusetts General Hospital
Laurence Lamson Robbins Professor of Radiology:
Harvard Medical School

 

 

Peter Conti, MD

Director, PET Imaging Science Center;
Professor:
Radiology, Division of Nuclear Medicine; Clinical Pharmacy; Biomedical Engineering
Keck School of Medicine 
School of Pharmacy
,
Viterbi School of Engineering,
University of Southern California

 

 

Jason Lewis, PhD

Director, Center for Molecular Imaging and Nanotechnology;
Chief, Radiochemistry and Imaging Science Service;
Vice Chair for Research, Department of Radiology;
Emily Tow Jackson Chair in Oncology:
Memorial Sloan–Kettering Cancer Center

 

 

 

Dwaine Rieves, MD

Pharmaceutical Consultant;
Former Director, Division of Medical Imaging Products:
FDA